Allergy Therapeutics Share Discussion Threads

[richsawko] 19/4/2017 09:47

So potential competition have ceased study - could be very positive for AGY

[lordshaw] 19/4/2017 09:39

Meanwhile, news from Circassia, one of Neil Woodford's investments:

Oxford, UK - 18 April 2017: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces top-line results from its investigational house dust mite allergy immunotherapy phase IIb field study. In the study, both the active treatment and placebo greatly reduced subjects' allergy symptoms and rescue medication use. As a result, the treatment did not show a significant effect compared with placebo and the study did not meet its primary endpoint. The results show the immunotherapy was well tolerated with a highly favourable safety profile.

Steve Harris, Circassia's Chief Executive, said: "We are naturally disappointed by this outcome, which is in line with our cat allergy phase III study where there was also a very marked placebo effect. Although subjects receiving the immunotherapies in both these studies had greatly improved allergy symptoms, the strong placebo effect made it highly challenging to achieve the studies' endpoints."

"It is concerning that in two well-designed field trials, a robust placebo response has confounded our ability to demonstrate a significant treatment effect, despite positive results in earlier chamber studies. We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio. As indicated previously, we will now focus on our wider respiratory business, in particular our new US commercial collaboration with AstraZeneca, our market-leading NIOX(R) franchise and the development of our broader respiratory portfolio."

Next steps

Following the receipt of disappointing cat allergy phase III results in June last year, Circassia halted significant new investment in its allergy portfolio while awaiting the outcome of its house dust mite field study. Following these new results, Circassia will make no further investment in its allergy programmes.

[shauney2] 18/4/2017 15:05

Aborted take off.

[shauney2] 12/4/2017 15:55

Looks like they have carried him off and its away.

[shauney2] 12/4/2017 12:03

Lets hope it doesn't turn into a United Airlines flight.

[jimmyloser] 12/4/2017 11:55

At the gate and awaiting takeoff!

[audigger] 10/4/2017 17:27

Looks like someone could be mopping-up a chunk of these. are we about to finally ping above 30p and beyond?

[jimmyloser] 07/4/2017 12:02

Start of the tax year and that balances last weeks trades as I see it.

[richsawko] 07/4/2017 11:48

Another 2.5 million shares at 27.5p - is someone building a holding?

[jimmyloser] 05/4/2017 07:22

New Hardman research note this morning

cs‐documents/agy‐interimR08;resultsupdateR08;
5th‐april.pdf

[richsawko] 31/3/2017 12:55

WOW 2.5 MILLION SHARES JUST SOLD at 27p - what could this mean?

[shauney2] 30/3/2017 16:20

Good intraday recovery.Through 29p could be very bullish.

[jimmyloser] 29/3/2017 16:42

Director buying?

These mm's smell news - lol

I should bloody think so, it took long enough to motor.

[audigger] 29/3/2017 16:39

Well we got some momentum! I missed that buying opportunity.

[oshy92] 29/3/2017 11:07

Morning
Short TV clip following results announcement today:
www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/

[richsawko] 29/3/2017 09:04

Now it's starting to motor - must be related to presentation and people waking up!!

[shauney2] 29/3/2017 08:59

Broker finnCap, which rates the shares a 'buy' said that apart from a slightly lower than expected first half R&D charge, “which is likely to be timing related”, it will make no change to its full-year forecasts.

“We retain a near term target price of 43p and point to the further upside that Pollinex Quattro (PQ) Grass programme in the US offers investors,” the broker said.

[audigger] 29/3/2017 08:36

The cash burn will be dictated by the cost of their various trials so it will come in chunks. Their last raising was intended to cover the US grass opportunity so given the range finding trial didn't work as planned and the new opportunity in peanuts they will almost certainly need more cash as I doubt profitability in Europe will cover it. Of course there is always the possibility they may partner with a bigger outfit in the US so they would be a game changer. Selfishly I'd be happy with a further pull back in the short term readyy for my ISA top up!

[richsawko] 29/3/2017 08:22

Yeah, I would have expected us to jump to high 20's at least based on these results. Maybe waiting for presentation at 9am!

[jimmyloser] 29/3/2017 08:12

They have lots of new products all needing funding...Peanuts...it is just a hunch.
I am surprised at that lack of reaction to these results but as AuDigger stated
This is AIM

[richsawko] 29/3/2017 08:00

I didn't see any description of drawdown of funds which could trigger raising more cash - did I miss this in the statement. Do we know what the cash burn rate is for the next year?

[jimmyloser] 29/3/2017 07:53

Rich,
Perhaps they are keeping their powder dry for another RNS!
The name of the game here now is to get that share price up before they raise more cash.

impo/dyor.

[richsawko] 29/3/2017 07:41

Yes good results showing consistent growth - would have liked a bit more of an update on US trials though

[audigger] 29/3/2017 07:34

Solid. One would like to think the share price will react accordingly but being AIM anything is possible!